<DOC>
	<DOCNO>NCT00379600</DOCNO>
	<brief_summary>To assess whether anti-inflammatory effect rosiglitazone result improvement Rheumatoid Arthritis symptoms patient exist Disease Modifying Anti-Rheumatic Drug ( DMARD ) treatment give adequate relief .</brief_summary>
	<brief_title>The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Rheumatoid Arthritis insufficiently control exist diseasemodifying antirheumatic drug Subjects least 6 swollen joint plus 2 following : 6 tender joint ( 28 joint ) ; early morning stiffness last 30 minute ; ESR great equal 28mm/h must receive stable dose diseasemodifying antirheumatic therapy least 2 month prior participate study . Exclusion criterion : Women lactate , pregnant , plan become pregnant course study include 30 day follow conclusion study medication Systolic blood pressure ( SBP ) &gt; 165 mmHg diastolic blood pressure ( DBP ) &gt; 95 mmHg receive optimal antihypertensive therapy Any clinically significant abnormality identify screen physical exam , laboratory test , ECG , judgement Investigator make subject unsuitable inclusion study history alcohol abuse within past 3 year consumes &gt; 3 unit per day male &gt; 2 unit per day female history cirrhosis stigma chronic liver disease history liver disease alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level &gt; 2.5 time upper limit normal total bilirubin level great 1.5 time upper limit normal ( unless associate predominantly indirect bilirubin Gilbert 's syndrome ) screen use glucocorticoid dos &gt; 10 mg/day currently within last 3 month may expect course study The subject 's dose NSAIDs , COX2 inhibitor glucocorticoid change time past 2 week prior screen may expect change course study The subject 's dose treatment statin change time past 3 month prior screen may expect change course study history renal disease serum creatinine = 132mol/L male =130mol female diabetes mellitus require medication hyperglycaemia HbA1c &gt; 7 % History new cardiovascular event within last 6 month ( i.e. , intervention , percutaneous coronary intervention , vascular surgery , acute coronary syndrome [ non Qwave myocardial infarction , Qwave myocardial infarction , unstable angina ) significant arrhythmia ; major intervention ( e.g. , cardiac surgery angiography plus stenting ) schedule Concurrent past medical history congestive heart failure pulmonary oedema A presence severe peripheral oedema medically serious fluidrelated event significant cardiac , pulmonary , metabolic , renal , hepatic , gastrointestinal immunological condition , opinion Investigator and/or GSK medical monitor , place subject unacceptable risk participant trial history malignancy last 5 year , except surgically cure basal cell carcinoma ( &gt; 2 year prior first dose ) history HIV , chronic hepatitis B positive C serology history drug abuse participate clinical trial within 3 month start study nonbiological therapy ; within 6 month biological therapy biological therapy receive biological therapy within 6 month prior screen donate blood excess 500 mL within 56 day prior dose The subject risk noncompliance follow direction adhere study restriction history drug allergy , , opinion physician responsible , contraindicate participation anaemia define haemoglobin concentration &lt; 11 g/dL male &lt; 10 g/dL female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Anti-inflammatory treatment</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>